Liminatus Pharma Inc. Class A Common Stock (LIMN)

About LIMN

Liminatus Pharma, Inc., a pre-clinical stage biopharmaceutical company, engages in the development of cancer therapies in the United States. It develops IBA101, a humanized anti CD47 monoclonal antibody, which is in Phase I clinical trial for the treatment of advanced solid cancers, including non-small cell lung cancer. The company was founded in 2018 and is based in Cerritos, California.

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

1

Website

liminatuspharma.com

Fundamentals

1-day range

$0.1273$0.144

Market cap

$7.64M

P/E (trailing)

—

P/E (forward)

—

EPS (trailing)

$-0.25

Dividend yield

—

Beta

0.74

Avg. volume

41.04M

Liminatus Pharma Inc. Class A Common Stock Competitors

Chosen by industry and closest market cap.

• LIMN

  Liminatus Pharma Inc. Class A Common Stock

  $4.23

  ▼ 3.86%
  Market cap $7.64MP/E —
  $0.095$4.12
• AIM

  AIM ImmunoTech Inc. Common Stock

  $0.2558

  ▲ 2.32%
  Market cap $7.32MP/E —
  $0.1901$2.89
• BCDA

  BioCardia Inc. Common Stock

  $1.16

  ▼ 0.85%
  Market cap $9.45MP/E —
  $0.75$2.29
• BCAB

  BioAtla Inc. Common Stock

  $1.79

  ▼ 42.99%
  Market cap $5.41MP/E —
  $2.81$71.5
• CRIS

  Curis Inc. Common Stock

  $1.49

  ▲ 2.76%
  Market cap $10.04MP/E —
  $1.4$39
• PHGE

  BiomX Inc. COmmon Stock

  $0.138

  ▲ 4.55%
  Market cap $4.62MP/E —
  $0.1192$12.29
• VIVS

  VivoSim Labs Inc. Common Stock

  $0.29

  ▲ 0.00%
  Market cap $4.03MP/E —
  $0.2625$5.3

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

1.45M

Total value held

$184.9K

Institutional holders

14